Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
APIX Biosciences from Wingene, company number BE0771667563, closed financial year 2025 with a result of € -620,962 after tax. For that financial year APIX Biosciences recorded a gross margin of € -149,150 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € -95,737 to € -620,962. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on November 28, 2025.
€ 1.1 million
▼ 37% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -620,962
▼ 549 % more loss than in 2024
Profit after tax over the fiscal year.
€ 430,491
▲ € 405,357 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -829,300.
People and assets in 2025
4
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 427,628
▼ 1% vs 2024
€ 106,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 3,985
▲ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 4.5 million
▲ 29% vs 2024
Loans from banks and other lenders, long and short.
€ 224,926
▲ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 69,229
▲ 4% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -37,955 | € 31,858 | € 332,260 | € -149,150 | ▼ € 481,410 |
| Profit after taxes | € -23,770 | € -88,833 | € -95,737 | € -620,962 | ▼ € 525,225 |
| Equity | € 1,182,044 | € 1,793,327 | € 1,697,591 | € 1,076,629 | ▼ 37% |
| Total debts | € 619,975 | € 1,082,303 | € 3,716,009 | € 4,816,112 | ▲ 30% |
| Cash | € 345,006 | € 877,127 | € 25,134 | € 430,491 | ▲ € 405,357 |
| Retained profit | € -23,770 | € -112,602 | € -208,339 | € -829,300 | ▼ € 620,962 |
| Bank debt | € 300,000 | € 1,000,000 | € 3,500,000 | € 4,500,000 | ▲ 29% |
| Balance sheet total | € 1,802,019 | € 2,875,631 | € 5,413,600 | € 5,892,741 | ▲ 9% |
| Employees (FTE) | - | 0.9 | 3.8 | 4 | ▲ 0.2 |
Key figures of APIX Biosciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 November 2026.
What happened to APIX Biosciences?
What happened at APIX Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- DE LIER BV stepped down as director. NBB
- MAARTEN DUYCK stepped down as director. NBB
- MYRMEX BV stepped down as director. NBB
- THIERRY BOGAERT stepped down as director. NBB
- SHARON SHAFIR stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 620,962. Source: NBB ↗
- DE LIER BV became a director. NBB
- MAARTEN DUYCK became a director. NBB
In short
From € 23,770 loss in 2022 to € 620,962 loss in 2025.
On average € 87,400 of value added per employee in 2024.
A new publication or filing at APIX Biosciences? We notify you, reason included.
Follow APIX BiosciencesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 100% of APIX Biosciences Holdings Inc. and 100% of APIX Nutrition Ltd. itself.
Directors
According to the 2025 annual accounts
Director · represented by FRANCOIS VAN LIERDE
Also active at: ACKERMANS & VAN HAAREN, Protealis
since 2025 · until 2031
since 2021 · until 2027
since 2021 · until 2027
since 2025 · until 2031
SHARON SHAFIR
Director
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Blauwhuisstraat 11
8750 Wingene
Blauwhuisstraat 4
8750 Wingene
Active since 22 August 2021
Beernemsteenweg 77B
8750 Wingene
Active since 23 July 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →ALASAN
PARANG
Mellona
MYRMEX same network
€ 49,468 gross margin · 2025
Phytant same network
€ -2,064 gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0771.667.563
- VAT number
- BE 0771.667.563
- Registered office
- Blauwhuisstraat 11, 8750 Wingene
- Names & denominations
- APIX Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 July 2021
- Peppol
- Active · Active since 11 Aug 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Diverse administratieve activiteiten ten behoeve van kantoren
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied